http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101919240-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_465b607edb4c88aeefb4958e154efaec |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-03 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-721 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-102 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 |
| filingDate | 2017-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8267fabb70bfbd8804b2e1f8e89b2703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f23e6201071238cbd273ff295d8890c |
| publicationDate | 2018-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101919240-B1 |
| titleOfInvention | Liver fibrosis inducible recombinant vector and the method for producing animal model using thereof |
| abstract | The present invention relates to an induction vector for liver fibrosis and an animal model using the same. According to the present invention, the Cas9-ERT2 protein complex can be transferred from the cytoplasm to the nucleus by treating Tamoxifen at a certain point, The protein complex, which has migrated into the nucleus, can transform a specific DNA more precisely at a desired point through a guide RNA (gRNA). In particular, treatment of tamoxifen with the Cas9-ERT2 complex fused with the gRNA of TIF1 gamma inhibiting gene of hepatic fibrosis and the liver cell-specific promoter can knock out the TIF1 gamma gene to induce liver fibrosis. TIF1 gamma is a very important factor in the prevention and treatment of liver fibrosis or cirrhosis. Therefore, the present invention can be used to develop a technique for analyzing liver fibrosis disease, and furthermore, a clinical study such as candidate drug screening for liver fibrosis treatment And can be used to identify new proteins that can be a target of new drug development. |
| priorityDate | 2017-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 219.